Diabetes Clinical Trials Market Size to Reach USD 10.02 Billion by 2034 at a 7.9% CAGR from 2026 to 2034
The diabetes clinical trials market size was valued at USD 5.06 billion in 2025 and is expected to reach USD 10.02 billion by 2034, growing at a CAGR of 7.9%. Rising adoption of decentralized clinical trials and wearable glucose monitoring technologies is supporting market expansion globally.
Key Statistics:
- Market Size (2025): USD 5.06 Billion
- Market Size (2034): USD 10.02 Billion
- CAGR (2026-2034): 7.9%
- Dominating Region: North America
Report Highlights:
- North America dominated the market in 2025 with 41.0% share, due to strong pharmaceutical R&D investments and advanced clinical research infrastructure.
- Phase III trials dominated the market in 2025 with 43.0% share, due to increasing late-stage commercialization studies for diabetes therapeutics.
- GLP-1 receptor agonist trials dominated the market in 2025 capturing 29.0% share driven by rising investment in obesity-linked diabetes therapies.
- Decentralized clinical trials are projected to grow at the fastest CAGR of 10.5% during the forecast period owing to increasing use of AI-enabled recruitment and remote patient monitoring systems.
- Key companies operating in the market include AbbVie Inc., AstraZeneca PLC, Biocon Limited, Boehringer Ingelheim International GmbH, Eli Lilly and Company, GlaxoSmithKline PLC, Johnson & Johnson, Merck & Co., Inc., Novo Nordisk A/S, Novartis AG, Pfizer Inc., Sanofi S.A., Servier Laboratories Pvt. Ltd., Takeda Pharmaceutical Company Limited, and Wockhardt Limited.
What’s Included in Diabetes Clinical Trials Report?
The report provides a detailed overview of the diabetes clinical trials market based on trial phase, study design, therapy type, and end user. It includes regional analysis, industry dynamics, and competitive landscape.
What are Driving Factors and Emerging Trends of Diabetes Clinical Trials Market?
As per analysis, the market is expanding due to increasing diabetes burden and growing investment in advanced metabolic disease therapies. Key growth factors include:
- Increasing Demand for Diabetic and Metabolic Diseases Drugs: With increasing cases of diabetic conditions in both developed and developing countries, there is increased demand for new diabetic drugs research.
- Expanding Business Potential for GLP-1 Drugs: The rising business potential and successes seen in GLP-1 receptor agonists have increased investments in the field of obese type 2 diabetes drugs and cardiometabolic diseases.
- AI-Driven Decentralized Clinical Trials: Artificial intelligence as well as decentralized clinical trial systems have made patient enrollment more efficient and helped with analyzing trial data in diabetes studies.
These trends indicate a strong transition toward digitally connected and patient-centric diabetes clinical research ecosystems.
Request a free sample copy or read the full market insights: Diabetes Clinical Trials Market Report
Which Key Segments are Driving Diabetes Clinical Trials Market?
By Trial Phase Analysis
Phase III trials segment accounted for the largest share in 2025 due to rising commercialization activity for GLP-1 receptor agonists, insulin analogs, and cardiovascular outcome therapies.
By Study Design Analysis
Interventional studies segment dominated the market in 2025 driven by increasing regulatory approval requirements and rising demand for therapeutic efficacy validation across diabetes treatment pipelines.
Which is Dominating Region in Diabetes Clinical Trials Market?
North America: North America led the market due to strong pharmaceutical R&D infrastructure, high diabetes prevalence, and increasing investments in GLP-1 diabetes studies and AI-enabled clinical research platforms across the US and Canada.
Asia Pacific: Asia Pacific is projected to grow at the fastest pace driven by rising diabetes incidence, expanding CRO ecosystems, and increasing pharmaceutical outsourcing activities across China, India, Japan, and South Korea.
Where is Diabetes Clinical Trials Market Headed?
According to analysis, the market is expected to witness strong expansion supported by increasing investment in metabolic disease therapies, rising adoption of decentralized clinical trials, and growing integration of AI-powered patient recruitment and digital monitoring technologies.
What Diabetes Clinical Trials Market Report Reveals?
- What is the global market size, growth trend, and CAGR for the diabetes clinical trials market through 2034?
- What are the key factors driving the growth of the diabetes clinical trials market?
- Who are the key players in the diabetes clinical trials market, and what is their competitive positioning?
- What effect is higher prevalence of diabetes having on the global clinical trials market?
- What role do GLP-1 receptor agonists and decentralized trial platforms play in market expansion?
- What are the key regional trends across North America, Europe, and Asia Pacific?
- Where do new opportunities arise in the diabetes clinical trials market?
Who are Major Diabetes Clinical Trials Market Contributors?
According to our study, a few firms are leading in the global market. The following are some of the major market contributors:
- AbbVie Inc.
- AstraZeneca PLC
- Biocon Limited
- Boehringer Ingelheim International GmbH
- Eli Lilly and Company
- GlaxoSmithKline PLC
- Johnson & Johnson
- Merck & Co., Inc.
- Novo Nordisk A/S
- Novartis AG
- Pfizer Inc.
- Sanofi S.A.
- Servier Laboratories Pvt. Ltd.
- Takeda Pharmaceutical Company Limited
- Wockhardt Limited
Market Segments Covered
By Trial Phase Outlook (Revenue, USD Billion, 2021–2035)
- Phase I
- Phase II
- Phase III
- Phase IV
By Study Design Outlook (Revenue, USD Billion, 2021–2035)
- Interventional Studies
- Observational Studies
- Decentralized Clinical Trials
By Therapy Type Outlook (Revenue, USD Billion, 2021–2035)
- GLP-1 Receptor Agonists
- SGLT2 Inhibitors
- Insulin Analogs
- Gene Therapies
- Combination Therapies
- Others
By End User Outlook (Revenue, USD Billion, 2021–2035)
- Pharmaceutical & Biotechnology Companies
- Contract Research Organizations (CROs)
- Academic Research Institutes
- Hospitals & Specialty Clinics
By Regional Outlook (Revenue, USD Billion, 2021-2034)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Netherland
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Malaysia
- South Korea
- Indonesia
- Australia
- Rest of Asia Pacific
- Latin America
- Mexico
- Brazil
- Argentina
- Rest of Latin America
- Middle East & Africa
- Saudi Arabia
- UAE
- South Africa
- Israel
- Rest of Middle East & Africa
